A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis

Table 1 Characteristics of the patients at baseline

	All PBC cases	Cases with nizatidine	Cases without nizatidine	P value
No. of cases	73	27	46
Age (mean ± SD)	65.6 ± 12.2	68.2 ± 11.8	64.1 ± 12.3	0.32
Sex (male/female)	9 (18%)/64 (88%)	4(%)/23(%)	5 (18%)/41 (88%)	0.72
Histological classifications	24/8/3/2	11/1/0/0	13/7/3/2	0.12
Scheuer (1/2/3/4)	65%/22%/8%/5%	92%/8%/0%/0%	52%/26%/12%/8%
Alb (g/dL)	4.0 ± 0.3	4.1 ± 0.3	4.0 ± 0.4	0.50
ChE (IU/L)	288.3 ± 66.4	302.2 ± 68.5	277.9 ± 64.0	0.24
AST (IU/L)	55.6 ± 47.3	64.6 ± 44.5	50.3 ± 48.5	0.10
ALT (IU/L)	58.2 ± 64.6	75.7 ± 67.0	48.0 ± 61.5	0.04
γGTP (IU/L)	183.8 ± 205.6	221.0 ± 254.7	162.0 ± 169.8	0.10
ALP (IU/L)	638.7 ± 446.8	661.0 ± 616.3	625.7 ± 315.5	0.12
T-Bil (mg/dL)	0.69 ± 0.37	0.71 ± 0.33	0.67 ± 0.39	0.33
Plt (× 104/μL)	21.7 ± 8.8	23.2 ± 10.9	20.7 ± 7.3	0.74
M2 antibody (< 5/5)	17 (23%)/56 (77%)	9 (33%)/18 (67%)	8 (17%)/38 (83%)	0.15
ANA (< 40/40)	23 (32%)/50 (68%)	7 (26%)/20 (74%)	16 (35%)/30 (65%)	0.60
Collagen disease complication (presence/absence)	45 (62%)/28 (38%)	13 (48%)/14 (52%)	32 (70%)/14 (30%	0.08

PBC: Primary biliary cirrhosis; Alb: Albumin; ChE: Cholinesterase; AST: Aspartate aminotransaminase; ALT: Alanine aminotransaminase; γGTP: γ-glutamyltranspeptidase; ALP: Alkaline phosphatase; T-Bil: Total bilirubin; Plt: Platelet; ANA: Anti-nuclear antibody.

Table 2 The effects of the administration of nizatidine on the nutritional condition, the hepatic functional reserve, and the long-term prognosis of primary biliary cirrhosis

	Nizatidine administration group (n = 27)			Nizatidine non-administration group (n = 46)
	Before administration	24 mo	P value	Before treatment	24 mo	P value
Alb	4.1 ± 0.3	4.2 ± 0.3	0.41	4.0 ± 0.4	4.1 ± 0.3	0.67
ChE	302.2 ± 68.5	314.0 ± 62.3	0.56	277.9 ± 64.0	286.5 ± 71.1	0.73
Child-Pugh score	5.1 ± 0.4	5.1 ± 0.4	0.59	5.0 ± 0.2	5.0 ± 0.2	0.99

Alb: Albumin; ChE: Cholinesterase.